7:30-8:50 am
Registration/Check-in
8:50-9:00 am
Welcoming Remarks
Gerry Boss, MD, University of California San Diego
SESSION I
Diana Hargreaves, PhD - Salk Institute (Moderator)
9:00-9:30 am
CD19 CAR-T Cells: Prototypes for the Living Drug Concept
Michel Sadelain, MD, PhD - Memorial Sloan Kettering Cancer Center
9:30-9:40 am
Discussion
9:40-10:10 am
Remote and Noninvasive Control of Genetics by Ultrasound for Cell Therapy Against Solid Tumors
Peter Yingxiao Wang, PhD, University of Southern California
10:10-10:20 am
Discussion
10:20-10:40 am
Break
SESSION II
Cosimo Commisso, PhD - Sanford Burnham Prebys (Moderator)
10:40-11:10 am
Off-The-Shelf NK Cell Strategies to Treat Cancer
Jeffrey S. Miller, MD - University of Minnesota
11:10-11:20 am
Discussion
11:20-11:50 am
Engineering Human Pluripotent Stem Cells to Produce Immune Cells with Improved Anti-tumor Activity
Dan Kaufman, MD, PhD - University of California San Diego
11:50-12:00 pm
Discussion
12:00-1:30 pm
Lunch
1:30-2:00 pm
Bench to Bedside Translation of a Novel Switchable CAR-T Cell Platform
Travis Young, PhD - Calibr at Scripps Research
2:00-2:10 pm
Discussion
SESSION III
Jing Yang, PhD - University of California San Diego (Moderator)
2:10-2:40 pm
From Cancer to Aging: Harnessing CAR-T Cells to Deconstruct Senescence
Corina Amor Vegas, MD, PhD - Cold Spring Harbor Laboratory
2:40-2:50 pm
Discussion
2:50-3:10 pm
Break
3:10-3:40 pm
Augmenting CAR-T with Engineered Interleukin-18
Aaron Ring, MD, PhD - Fred Hutchinson Cancer Center
3:40-3:50 pm
Discussion
3:50-4:20 pm
Bridging Synthetic Immunology and Genome Editing to Advance T Cell Therapies
Justin Eyquem, PhD - University of California San Francisco
4:20-4:30 pm
Discussion
4:30 pm
Closing Remarks
Dan Kaufman, MD, PhD - University of California San Diego